Clinical Trials

200 enrolled 12 charts

Multiple Myeloma

NCT01231412 2026-04-30

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

LymphoidMyeloidOther hematologic neoplasmPlasma cell

174 enrolled 12 charts

Hodgkin Disease, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00114101 2026-04-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

460 enrolled 11 charts

Smoldering Multiple Myeloma, Multiple Myeloma

NCT00602641 2026-04-29

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

306 enrolled 12 charts

Multiple Myeloma

NCT04246047 2026-04-23

DREAMM 7

494 enrolled 10 charts 1 FDA

Multiple Myeloma

NCT06868654 2026-04-23

DREAMM 7

72 enrolled 10 charts

Multiple Myeloma

NCT06868667 2026-04-23

DREAMM 7

24 enrolled 10 charts

Multiple Myeloma

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 11 charts 1 FDA

Multiple Myeloma

NCT04162210 2026-03-31

DREAMM-3

325 enrolled 10 charts

Multiple Myeloma

NCT03710603 2026-02-10

Perseus

709 enrolled 17 charts 1 FDA

Multiple Myeloma

NCT03275285 2026-02-09

IKEMA

302 enrolled 38 charts 1 FDA

Multiple Myeloma

NCT01208662 2026-01-22

DFCI 10-106

729 enrolled 29 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03246529 2026-01-15

GENESIS

180 enrolled 22 charts

Multiple Myeloma

NCT03180736 2025-12-19

EMN14

304 enrolled 19 charts 1 FDA

Multiple Myeloma

NCT02252172 2025-10-20

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

737 enrolled 30 charts 1 FDA

Multiple Myeloma

NCT04459416 2025-10-20

Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

299 enrolled 11 charts

LymphoidPlasma cell

Agnosia, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT01241708 2025-09-17

(Mel/MelVel)

148 enrolled 12 charts

Multiple Myeloma

NCT02136134 2025-08-29

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

498 enrolled 15 charts

Multiple Myeloma, Plasmacytoma

NCT02195479 2025-08-22

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

706 enrolled 29 charts

Multiple Myeloma

NCT06956170 2025-06-11

DREAMM 8

21 enrolled 9 charts

Multiple Myeloma

NCT03941860 2025-05-23

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

1 enrolled 1 chart

Multiple Myeloma

NCT03158688 2025-05-09

CANDOR

466 enrolled 33 charts 1 FDA

Multiple Myeloma

NCT02076009 2025-05-01

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

569 enrolled 18 charts

Multiple Myeloma

NCT03277105 2025-04-29

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

522 enrolled 26 charts 1 FDA

Multiple Myeloma

NCT02541383 2025-04-13

Cassiopeia

1,085 enrolled 22 charts 1 FDA

Multiple Myeloma

NCT03748953 2025-03-21

Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

37 enrolled 19 charts

Multiple Myeloma

NCT04484623 2025-03-18

DREAMM 8

302 enrolled 10 charts

Multiple Myeloma

NCT01539083 2025-02-04

VCAT

256 enrolled 13 charts

Multiple Myeloma

NCT02990338 2025-01-17

ICARIA-MM

307 enrolled 32 charts 1 FDA

Multiple Myeloma

NCT02181413 2024-11-19

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

656 enrolled 36 charts

Multiple Myeloma

NCT03110562 2024-08-21

BOSTON

402 enrolled 22 charts 1 FDA

Multiple Myeloma, Recurrence

NCT03859427 2024-08-13

ARROW2

454 enrolled 24 charts

Multiple Myeloma, Recurrence, Bone Marrow Neoplasms

NCT03151811 2024-01-30

OCEAN

495 enrolled 15 charts

Multiple Myeloma

NCT04549363 2023-12-13

Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin

16 enrolled 7 charts

Multiple Myeloma

NCT02312258 2023-09-21

A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

706 enrolled 29 charts

Multiple Myeloma

NCT00049673 2023-09-13

Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma

332 enrolled 11 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01951885 2023-09-11

Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention

LymphoidMyeloidOther hematologic neoplasmPlasma cell

101 enrolled 28 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02755597 2023-08-22

Bellini

291 enrolled 24 charts

Multiple Myeloma

NCT01850524 2023-07-21

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

705 enrolled 30 charts

Multiple Myeloma

NCT04649060 2023-06-08

LIGHTHOUSE

54 enrolled 21 charts

Multiple Myeloma

NCT01734928 2023-06-06

OPTIMISMM

559 enrolled 16 charts

Multiple Myeloma

NCT02516696 2023-06-05

BiRd vs Rd

12 enrolled 19 charts

Multiple Myeloma

NCT02726581 2023-03-27

CheckMate 602

170 enrolled 16 charts

Multiple Myeloma

NCT01564537 2023-03-10

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

722 enrolled 29 charts

Multiple Myeloma

NCT02609828 2023-02-16

Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy

156 enrolled 31 charts

Cancer Pain, Multiple Myeloma

NCT01568866 2022-11-14

ENDEAVOR

929 enrolled 21 charts

Multiple Myeloma

NCT01345019 2022-11-08

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Other hematologic neoplasmPlasma cellSarcoma

1,718 enrolled 22 charts

Blood Protein Disorders, Bone Diseases, Bone Marrow Diseases, Bone Neoplasms, Hematologic Diseases, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Paraproteinemias, Spinal Cord Compression, Hematologic Neoplasms, Fractures, Bone, Neoplasms, Plasma Cell

NCT00330759 2022-11-07

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

1,779 enrolled 14 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Spinal Cord Compression

NCT01335399 2022-09-30

ELOQUENT - 1

748 enrolled 15 charts